Agentic AI trust gap slowing healthcare provider adoption, survey reveals
A new survey from digital healthcare security specialist Imprivata has revealed that, while artificial intelligence (AI) is now becoming commonplace…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
GSK bolsters oncology pipeline with $750m Chimagen TCE deal
GSK has secured the rights to Chimagen Biosciences’ trispecific T-cell engager (TCE) for multiple myeloma, signalling the big pharma company’s…
-
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine,…
-
Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval
The US Food and Drug Administration (FDA) approved Scholar Rock’s rare neuromuscular disease therapy, Isemblyd (apitegromab), making it the first…
-
Staunch biotech competition spurs new secretive tactics, shifts investor approach
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to…
-
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s…
-
HHS appoints permanent FDA CBER, CDER heads
The US Department of Health and Human Services (HHS) has selected four senior leaders to assume permanent positions in the…
-
Pharma’s R&D, commercial approach shifts amid global policy evolution
A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch…
-
Moonwalk banks $70m to progress siRNA therapy for obesity
Moonwalk Biosciences has secured $70m in an oversubscribed, Eli Lilly-backed funding round to take its non-incretin obesity candidate to the…
-
UK on track to reverse years of pharma decline, ABPI report finds
The UK could be set to enter a pharma renaissance after a tricky few years punctuated with withdrawn investments, a…